Table II.
Time course observation of virological markers and hepatobiliary enzyme levels.
| Parametersd | Baseline | 3 months | 6 months | P-valuee |
|---|---|---|---|---|
| Total, n=33 | ||||
| HBeAg-positive | 11 (33%) | 10 (30%) | 10 (30%) | 1.0000 |
| HBV DNA positive, >1.3 Log IU/ml | 0 (0%) | 0 (0%) | 0 (0%) | |
| HBsAg, IU/ml | 1,126±1,724 | 1,032±1,648 | 1,001±1,591 | 0.0001c |
| AST, U/l | 24.9±7.7 | 23.5±6.6 | 26.6±14.2 | 0.7459 |
| ALT, U/l | 23.1±11.1 | 22.6±12.4 | 24.5±14.5 | 0.5044 |
| ALP, U/l | 320±126 | 295±135 | 283±124 | 0.028a |
| BAP, µg/l | 19.7±9.0 | N/A | 17.7±8.0 | 0.0006c |
| Total bilirubin, mg/dl | 0.9±0.3 | 0.9±0.3 | 0.9±0.3 | 0.9821 |
| Long-term group, n=19 | ||||
| HBsAg IU/ml | 590±641 | 523±613 | 537±598 | 0.0108a |
| AST, U/l | 25.5±9.5 | 23.9±6.7 | 24.0±7.1 | 0.2982 |
| ALT, U/l | 24.6±13.5 | 23.5±15.3 | 22.2±12.4 | 0.1329 |
| ALP, U/l | 324±141 | 310±159 | 302±151 | 0.0281a |
| BAP, µg/l | 21.1±11.0 | N/A | 19.2±9.7 | 0.0678 |
| Total bilirubin, mg/dl | 0.9±0.3 | 0.9±0.3 | 0.9±0.3 | 0.1221 |
| Short-term group, n=14 | ||||
| HBsAg, IU/ml | 1,853±2,400 | 1,796±2,350 | 1,631±2,235 | 0.004b |
| AST, U/l | 24.1±4.3 | 23.0±6.6 | 30.1±20.2 | 0.4121 |
| ALT, U/l | 21.1±6.4 | 21.2±6.1 | 27.6±16.9 | 0.5093 |
| ALP, U/l | 298±86 | 255±73 | 257±69 | 0.005b |
| BAP, µg/l | 17.9±5.1 | N/A | 15.5±4.6 | 0.0016b |
| Total bilirubin, mg/dl | 0.9±0.4 | 0.9±0.4 | 0.9±0.3 | 0.1016 |
aP<0.05,
bP<0.01,
cP<0.001.
dData are presented as the mean ± standard deviation or n (%).
eP-values are for the comparison between baseline and 6 months after tenofovir alafenamide switching. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BAP, bone specific alkaline phosphatase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; N/A, not available.